Skip to main content

Dr. Biruh Workeneh, MD

Nephrology (Kidney) (Nephrology Physician)

  • Medicare participating

At a glance

Years since graduation
24
In the NPI registry since
2006
Medicare patients seen, 2024
286

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2002Medical school: University of Texas Medical School at Houston
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nephrology Physician primary
    TX license NO565
  • Internal Medicine Physician
    CA license A91837

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nephrology (Kidney) per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
286
Services billed
758
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes294128
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes6666
Established patient office or other outpatient visit, 30-39 minutes4037
Critical care, first 30-74 minutes3717
Hemodialysis procedure with physician evaluation3422
New patient office or other outpatient visit, 60-74 minutes2929
Telephone medical discussion with physician, 21-30 minutes1313

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 17 companies reported 83 payments worth $42,843 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$26,792
Consulting Fee$6,520
Travel and Lodging$5,951
Food and Beverage$3,580

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Dec 19, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Oct 8, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 8, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Oct 29, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Feb 11, 2025Travere Therapeutics, Inc.
Feb 11, 2025
Consulting Fee$3,600
Mar 20, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Mar 20, 2025
Consulting Fee$2,920
Dec 10, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Dec 10, 2025
Travel and Lodging
travel to IOWA CITY, IA · in-kind
$1,387
Oct 23, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 23, 2025
Travel and Lodging
travel to JUPITER, FL · in-kind
$1,079
Oct 2, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 2, 2025
Travel and Lodging
travel to CREVE COEUR, MO · in-kind
$873
Apr 11, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)$822
All 25 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Dec 19, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Dec 10, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Dec 10, 2025
Travel and Lodging
travel to IOWA CITY, IA · in-kind
$1,387
Dec 7, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Dec 7, 2025
Travel and Lodging
travel to IOWA CITY, IA · in-kind
$252
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$191
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$50.00
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$49.00
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$34.46
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$31.55
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$15.61
Nov 21, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 21, 2025
Travel and Lodging
travel to JUPITER, FL
$8.00
Nov 15, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 15, 2025
Travel and Lodging
travel to MURRAY, UT · in-kind
$172
Nov 13, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 13, 2025
Travel and Lodging
travel to MURRAY, UT · in-kind
$779
Oct 29, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Oct 23, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 23, 2025
Travel and Lodging
travel to JUPITER, FL · in-kind
$1,079
Oct 8, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 8, 2025
Compensation for services other than consulting (speaking, faculty)$6,424
Oct 4, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 4, 2025
Travel and Lodging
travel to CREVE COEUR, MO · in-kind
$185
Oct 2, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Oct 2, 2025
Travel and Lodging
travel to CREVE COEUR, MO · in-kind
$873
Jun 6, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Jun 6, 2025
Compensation for services other than consulting (speaking, faculty)$274
Apr 11, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)$822
Mar 20, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Mar 20, 2025
Consulting Fee$2,920
Feb 11, 2025Travere Therapeutics, Inc.
Feb 11, 2025
Consulting Fee$3,600
Feb 11, 2025Travere Therapeutics, Inc.
Feb 11, 2025
Travel and Lodging
travel to Dallas, TX · in-kind
$60.00
Jan 18, 2025Travere Therapeutics, Inc.
Jan 18, 2025
Travel and Lodging
Filspari · Kidney Disease · travel to Dallas, TX · in-kind
$480
Jan 18, 2025Travere Therapeutics, Inc.
Jan 18, 2025
Travel and Lodging
Filspari · Kidney Disease · travel to Dallas, TX · in-kind
$304

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $393,300 in research payments for these studies, mostly to the institutions running them.

  • Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE
    Genentech, Inc.
  • Phase 2b Open-Label Repeat Kidney Biopsy Study
    Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT06740526
  • Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
    Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646
  • Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
    Sanofi US Services Inc. · Active, not recruiting · NCT05039840
  • PoCP study in FSGS
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
    Novartis Pharmaceuticals Corporation
  • An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Houston

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 30, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1245339928. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.